ValuEngine Upgrades Cleveland BioLabs (NASDAQ:CBLI) to Buy

ValuEngine upgraded shares of Cleveland BioLabs (NASDAQ:CBLI) from a hold rating to a buy rating in a research report report published on Saturday, ValuEngine reports.

Shares of NASDAQ CBLI opened at $1.07 on Friday. Cleveland BioLabs has a 12 month low of $0.50 and a 12 month high of $2.16. The company has a market cap of $12.09 million, a price-to-earnings ratio of -5.09 and a beta of 0.74. The business has a fifty day simple moving average of $0.72 and a 200-day simple moving average of $1.01.

Cleveland BioLabs (NASDAQ:CBLI) last announced its earnings results on Thursday, November 14th. The biotechnology company reported ($0.04) EPS for the quarter. Cleveland BioLabs had a negative net margin of 241.79% and a negative return on equity of 93.20%. The company had revenue of $0.27 million for the quarter.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines.

Read More: What is a stock buyback?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.